{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T10:57:09Z","timestamp":1789815429213,"version":"4.0.1"},"publisher-location":"Singapore","reference-count":70,"publisher":"Springer Singapore","isbn-type":[{"value":"9789811086830","type":"print"},{"value":"9789811086847","type":"electronic"}],"license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018]]},"DOI":"10.1007\/978-981-10-8684-7_8","type":"book-chapter","created":{"date-parts":[[2018,6,28]],"date-time":"2018-06-28T07:26:36Z","timestamp":1530170796000},"page":"95-110","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["The Influence of Gut Microbial Metabolism on the Development and Progression of Non-alcoholic Fatty Liver Disease"],"prefix":"10.1007","author":[{"given":"Wei","family":"Jia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Rajani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,6,29]]},"reference":[{"key":"8_CR1","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.atherosclerosis.2015.01.001","volume":"239","author":"NN Than","year":"2015","unstructured":"Than NN, Newsome PN. A concise review of non-alcoholic fatty liver disease. Atherosclerosis. 2015;239:192\u2013202.","journal-title":"Atherosclerosis"},{"key":"8_CR2","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.jhep.2006.06.013","volume":"45","author":"M Machado","year":"2006","unstructured":"Machado M, Marques-Vidal P, Cortez-Pinto H. Hepatic histology in obese patients undergoing bariatric surgery. J Hepatol. 2006;45:600\u20136.","journal-title":"J Hepatol"},{"key":"8_CR3","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1111\/j.1365-2036.2011.04724.x","volume":"34","author":"G Vernon","year":"2011","unstructured":"Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011;34:274\u201385.","journal-title":"Aliment Pharmacol Ther"},{"key":"8_CR4","doi-asserted-by":"publisher","first-page":"481893","DOI":"10.1155\/2013\/481893","volume":"2013","author":"BM Attar","year":"2013","unstructured":"Attar BM, Van Thiel DH. Current concepts and management approaches in nonalcoholic fatty liver disease. Sci World J. 2013;2013:481893.","journal-title":"Sci World J"},{"key":"8_CR5","first-page":"1544","volume":"5","author":"M Gaggini","year":"2013","unstructured":"Gaggini M, Morelli M, Buzzigoli E, DeFronzo RA, Bugianesi E, Gastaldelli A. Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease. Forum Nutr. 2013;5:1544\u201360.","journal-title":"Forum Nutr"},{"key":"8_CR6","doi-asserted-by":"publisher","first-page":"300","DOI":"10.3390\/ijms17030300","volume":"17","author":"X He","year":"2016","unstructured":"He X, Ji G, Jia W, Li H. Gut microbiota and nonalcoholic fatty liver disease: insights on mechanism and application of metabolomics. Int J Mol Sci. 2016;17:300.","journal-title":"Int J Mol Sci"},{"key":"8_CR7","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1136\/gutjnl-2015-309990","volume":"65","author":"JR Marchesi","year":"2016","unstructured":"Marchesi JR, Adams DH, Fava F, Hermes GD, Hirschfield GM, Hold G, et al. The gut microbiota and host health: a new clinical frontier. Gut. 2016;65:330\u20139.","journal-title":"Gut"},{"key":"8_CR8","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1136\/gutjnl-2012-303816","volume":"62","author":"T Roy Le","year":"2013","unstructured":"Le Roy T, Llopis M, Lepage P, Bruneau A, Rabot S, Bevilacqua C, et al. Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice. Gut. 2013;62:1787\u201394.","journal-title":"Gut"},{"key":"8_CR9","doi-asserted-by":"publisher","first-page":"e1668","DOI":"10.1371\/journal.pone.0001668","volume":"3","author":"JF Fearnside","year":"2008","unstructured":"Fearnside JF, Dumas ME, Rothwell AR, Wilder SP, Cloarec O, Toye A, et al. Phylometabonomic patterns of adaptation to high fat diet feeding in inbred mice. PLoS One. 2008;3:e1668.","journal-title":"PLoS One"},{"key":"8_CR10","doi-asserted-by":"publisher","first-page":"4948","DOI":"10.1096\/fj.10-164921","volume":"24","author":"S Rabot","year":"2010","unstructured":"Rabot S, Membrez M, Bruneau A, Gerard P, Harach T, Moser M, et al. Germ-free C57BL\/6J mice are resistant to high-fat-diet-induced insulin resistance and have altered cholesterol metabolism. FASEB J. 2010;24:4948\u201359.","journal-title":"FASEB J"},{"key":"8_CR11","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1073\/pnas.0605374104","volume":"104","author":"F Backhed","year":"2007","unstructured":"Backhed F, Manchester JK, Semenkovich CF, Gordon JI. Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proc Natl Acad Sci U S A. 2007;104:979\u201384.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"8_CR12","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1136\/gutjnl-2011-301012","volume":"61","author":"M Serino","year":"2012","unstructured":"Serino M, Luche E, Gres S, Baylac A, Berge M, Cenac C, et al. Metabolic adaptation to a high-fat diet is associated with a change in the gut microbiota. Gut. 2012;61:543\u201353.","journal-title":"Gut"},{"key":"8_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.plipres.2008.08.001","volume":"48","author":"G Musso","year":"2009","unstructured":"Musso G, Gambino R, Cassader M. Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD). Prog Lipid Res. 2009;48:1\u201326.","journal-title":"Prog Lipid Res"},{"key":"8_CR14","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/nature10809","volume":"482","author":"J Henao-Mejia","year":"2012","unstructured":"Henao-Mejia J, Elinav E, Jin C, Hao L, Mehal WZ, Strowig T, et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature. 2012;482:179\u201385.","journal-title":"Nature"},{"key":"8_CR15","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s00284-010-9582-9","volume":"61","author":"X Wu","year":"2010","unstructured":"Wu X, Ma C, Han L, Nawaz M, Gao F, Zhang X, et al. Molecular characterisation of the faecal microbiota in patients with type II diabetes. Curr Microbiol. 2010;61:69\u201378.","journal-title":"Curr Microbiol"},{"key":"8_CR16","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1016\/j.jhep.2011.08.025","volume":"56","author":"LP Bechmann","year":"2012","unstructured":"Bechmann LP, Hannivoort RA, Gerken G, Hotamisligil GS, Trauner M, Canbay A. The interaction of hepatic lipid and glucose metabolism in liver diseases. J Hepatol. 2012;56:952\u201364.","journal-title":"J Hepatol"},{"key":"8_CR17","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1172\/JCI23621","volume":"115","author":"KL Donnelly","year":"2005","unstructured":"Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest. 2005;115:1343\u201351.","journal-title":"J Clin Invest"},{"key":"8_CR18","doi-asserted-by":"publisher","first-page":"31484","DOI":"10.1074\/jbc.M109.033936","volume":"284","author":"HY Liu","year":"2009","unstructured":"Liu HY, Han J, Cao SY, Hong T, Zhuo D, Shi J, et al. Hepatic autophagy is suppressed in the presence of insulin resistance and hyperinsulinemia: inhibition of FoxO1-dependent expression of key autophagy genes by insulin. J Biol Chem. 2009;284:31484\u201392.","journal-title":"J Biol Chem"},{"key":"8_CR19","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.biochi.2004.11.008","volume":"87","author":"R Dentin","year":"2005","unstructured":"Dentin R, Girard J, Postic C. Carbohydrate responsive element binding protein (ChREBP) and sterol regulatory element binding protein-1c (SREBP-1c): two key regulators of glucose metabolism and lipid synthesis in liver. Biochimie. 2005;87:81\u20136.","journal-title":"Biochimie"},{"key":"8_CR20","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.febslet.2007.07.084","volume":"582","author":"PD Denechaud","year":"2008","unstructured":"Denechaud PD, Dentin R, Girard J, Postic C. Role of ChREBP in hepatic steatosis and insulin resistance. FEBS Lett. 2008;582:68\u201373.","journal-title":"FEBS Lett"},{"key":"8_CR21","first-page":"221","volume":"7","author":"A Berlanga","year":"2014","unstructured":"Berlanga A, Guiu-Jurado E, Porras JA, Auguet T. Molecular pathways in non-alcoholic fatty liver disease. Clin Exp Gastroenterol. 2014;7:221\u201339.","journal-title":"Clin Exp Gastroenterol"},{"key":"8_CR22","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1124\/pr.113.008201","volume":"66","author":"T Li","year":"2014","unstructured":"Li T, Chiang JY. Bile acid signaling in metabolic disease and drug therapy. Pharmacol Rev. 2014;66:948\u201383.","journal-title":"Pharmacol Rev"},{"key":"8_CR23","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1073\/pnas.0506982103","volume":"103","author":"Y Zhang","year":"2006","unstructured":"Zhang Y, Lee FY, Barrera G, Lee H, Vales C, Gonzalez FJ, et al. Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc Natl Acad Sci U S A. 2006;103:1006\u201311.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"8_CR24","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1016\/j.bcp.2013.08.015","volume":"86","author":"Y Li","year":"2013","unstructured":"Li Y, Jadhav K, Zhang Y. Bile acid receptors in non-alcoholic fatty liver disease. Biochem Pharmacol. 2013;86:1517\u201324.","journal-title":"Biochem Pharmacol"},{"key":"8_CR25","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1053\/jhep.2003.50307","volume":"38","author":"E Ip","year":"2003","unstructured":"Ip E, Farrell GC, Robertson G, Hall P, Kirsch R, Leclercq I. Central role of PPARalpha-dependent hepatic lipid turnover in dietary steatohepatitis in mice. Hepatology. 2003;38:123\u201332.","journal-title":"Hepatology"},{"key":"8_CR26","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.hepres.2004.06.004","volume":"30","author":"PV Kashireddy","year":"2004","unstructured":"Kashireddy PV, Rao MS. Lack of peroxisome proliferator-activated receptor alpha in mice enhances methionine and choline deficient diet-induced steatohepatitis. Hepatol Res. 2004;30:104\u201310.","journal-title":"Hepatol Res"},{"key":"8_CR27","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1002\/hep.20170","volume":"39","author":"E Ip","year":"2004","unstructured":"Ip E, Farrell G, Hall P, Robertson G, Leclercq I. Administration of the potent PPARalpha agonist, Wy-14,643, reverses nutritional fibrosis and steatohepatitis in mice. Hepatology. 2004;39:1286\u201396.","journal-title":"Hepatology"},{"key":"8_CR28","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/j.bbalip.2011.10.016","volume":"1821","author":"A Tailleux","year":"2012","unstructured":"Tailleux A, Wouters K, Staels B. Roles of PPARs in NAFLD: potential therapeutic targets. Biochim Biophys Acta. 2012;1821:809\u201318.","journal-title":"Biochim Biophys Acta"},{"key":"8_CR29","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.cmet.2013.03.019","volume":"17","author":"WL Holland","year":"2013","unstructured":"Holland WL, Adams AC, Brozinick JT, Bui HH, Miyauchi Y, Kusminski CM, et al. An FGF21-adiponectin-ceramide axis controls energy expenditure and insulin action in mice. Cell Metab. 2013;17:790\u20137.","journal-title":"Cell Metab"},{"key":"8_CR30","doi-asserted-by":"publisher","first-page":"34533","DOI":"10.1074\/jbc.M111.248591","volume":"286","author":"X Ge","year":"2011","unstructured":"Ge X, Chen C, Hui X, Wang Y, Lam KS, Xu A. Fibroblast growth factor 21 induces glucose transporter-1 expression through activation of the serum response factor\/Ets-like protein-1 in adipocytes. J Biol Chem. 2011;286:34533\u201341.","journal-title":"J Biol Chem"},{"key":"8_CR31","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/S0016-5085(03)00896-5","volume":"125","author":"T Claudel","year":"2003","unstructured":"Claudel T, Inoue Y, Barbier O, Duran-Sandoval D, Kosykh V, Fruchart J, et al. Farnesoid X receptor agonists suppress hepatic apolipoprotein CIII expression. Gastroenterology. 2003;125:544\u201355.","journal-title":"Gastroenterology"},{"key":"8_CR32","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1172\/JCI0214505","volume":"109","author":"T Claudel","year":"2002","unstructured":"Claudel T, Sturm E, Duez H, Torra IP, Sirvent A, Kosykh V, et al. Bile acid-activated nuclear receptor FXR suppresses apolipoprotein A-I transcription via a negative FXR response element. J Clin Invest. 2002;109:961\u201371.","journal-title":"J Clin Invest"},{"key":"8_CR33","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.cmet.2007.05.003","volume":"5","author":"T Inagaki","year":"2007","unstructured":"Inagaki T, Dutchak P, Zhao G, Ding X, Gautron L, Parameswara V, et al. Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. Cell Metab. 2007;5:415\u201325.","journal-title":"Cell Metab"},{"key":"8_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10166","volume":"6","author":"C Jiang","year":"2015","unstructured":"Jiang C, Xie C, Lv Y, Li J, Krausz KW, Shi J, et al. Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction. Nat Commun. 2015;6:10166.","journal-title":"Nat Commun"},{"key":"8_CR35","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1053\/j.gastro.2016.08.057","volume":"151","author":"FJ Gonzalez","year":"2016","unstructured":"Gonzalez FJ, Jiang C, Patterson AD. An intestinal microbiota-Farnesoid X receptor Axis modulates metabolic disease. Gastroenterology. 2016;151:845\u201359.","journal-title":"Gastroenterology"},{"key":"8_CR36","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1126\/science.1198363","volume":"331","author":"S Kir","year":"2011","unstructured":"Kir S, Beddow SA, Samuel VT, Miller P, Previs SF, Suino-Powell K, et al. FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis. Science. 2011;331:1621\u20134.","journal-title":"Science"},{"key":"8_CR37","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.phrs.2015.12.007","volume":"104","author":"BL Copple","year":"2016","unstructured":"Copple BL, Li T. Pharmacology of bile acid receptors: evolution of bile acids from simple detergents to complex signaling molecules. Pharmacol Res. 2016;104:9\u201321.","journal-title":"Pharmacol Res"},{"key":"8_CR38","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1126\/science.284.5418.1365","volume":"284","author":"DJ Parks","year":"1999","unstructured":"Parks DJ, Blanchard SG, Bledsoe RK, Chandra G, Consler TG, Kliewer SA, et al. Bile acids: natural ligands for an orphan nuclear receptor. Science. 1999;284:1365\u20138.","journal-title":"Science"},{"key":"8_CR39","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1126\/science.284.5418.1362","volume":"284","author":"M Makishima","year":"1999","unstructured":"Makishima M, Okamoto AY, Repa JJ, Tu H, Learned RM, Luk A, et al. Identification of a nuclear receptor for bile acids. Science. 1999;284:1362\u20135.","journal-title":"Science"},{"key":"8_CR40","doi-asserted-by":"publisher","first-page":"9435","DOI":"10.1074\/jbc.M209706200","volume":"278","author":"Y Kawamata","year":"2003","unstructured":"Kawamata Y, Fujii R, Hosoya M, Harada M, Yoshida H, Miwa M, et al. A G protein-coupled receptor responsive to bile acids. J Biol Chem. 2003;278:9435\u201340.","journal-title":"J Biol Chem"},{"key":"8_CR41","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/S0006-291X(02)02550-0","volume":"298","author":"T Maruyama","year":"2002","unstructured":"Maruyama T, Miyamoto Y, Nakamura T, Tamai Y, Okada H, Sugiyama E, et al. Identification of membrane-type receptor for bile acids (M-BAR). Biochem Biophys Res Commun. 2002;298:714\u20139.","journal-title":"Biochem Biophys Res Commun"},{"key":"8_CR42","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1038\/nrd2619","volume":"7","author":"C Thomas","year":"2008","unstructured":"Thomas C, Pellicciari R, Pruzanski M, Auwerx J, Schoonjans K. Targeting bile-acid signalling for metabolic diseases. Nat Rev Drug Discov. 2008;7:678\u201393.","journal-title":"Nat Rev Drug Discov"},{"key":"8_CR43","doi-asserted-by":"publisher","first-page":"4430","DOI":"10.1172\/JCI86674","volume":"126","author":"S Fujisaka","year":"2016","unstructured":"Fujisaka S, Ussar S, Clish C, Devkota S, Dreyfuss JM, Sakaguchi M, et al. Antibiotic effects on gut microbiota and metabolism are host dependent. J Clin Invest. 2016;126:4430\u201343.","journal-title":"J Clin Invest"},{"key":"8_CR44","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.tem.2013.05.009","volume":"24","author":"AR Moschen","year":"2013","unstructured":"Moschen AR, Kaser S, Tilg H. Non-alcoholic steatohepatitis: a microbiota-driven disease. Trends Endocrinol Metab. 2013;24:537\u201345.","journal-title":"Trends Endocrinol Metab"},{"key":"8_CR45","doi-asserted-by":"publisher","first-page":"11070","DOI":"10.1073\/pnas.0504978102","volume":"102","author":"RE Ley","year":"2005","unstructured":"Ley RE, Backhed F, Turnbaugh P, Lozupone CA, Knight RD, Gordon JI. Obesity alters gut microbial ecology. Proc Natl Acad Sci U S A. 2005;102:11070\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"8_CR46","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1038\/4441022a","volume":"444","author":"RE Ley","year":"2006","unstructured":"Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: human gut microbes associated with obesity. Nature. 2006;444:1022\u20133.","journal-title":"Nature"},{"key":"8_CR47","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.2337\/dc10-0556","volume":"33","author":"G Musso","year":"2010","unstructured":"Musso G, Gambino R, Cassader M. Obesity, diabetes, and gut microbiota: the hygiene hypothesis expanded? Diabetes Care. 2010;33:2277\u201384.","journal-title":"Diabetes Care"},{"key":"8_CR48","doi-asserted-by":"publisher","first-page":"15718","DOI":"10.1073\/pnas.0407076101","volume":"101","author":"F Backhed","year":"2004","unstructured":"Backhed F, Ding H, Wang T, Hooper LV, Koh GY, Nagy A, et al. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci U S A. 2004;101:15718\u201323.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"8_CR49","doi-asserted-by":"publisher","first-page":"e13087","DOI":"10.1371\/journal.pone.0013087","volume":"5","author":"L Aronsson","year":"2010","unstructured":"Aronsson L, Huang Y, Parini P, Korach-Andre M, Hakansson J, Gustafsson JA, et al. Decreased fat storage by lactobacillus paracasei is associated with increased levels of angiopoietin-like 4 protein (ANGPTL4). PLoS One. 2010;5:e13087.","journal-title":"PLoS One"},{"key":"8_CR50","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s00418-013-1157-y","volume":"141","author":"S Alex","year":"2014","unstructured":"Alex S, Lichtenstein L, Dijk W, Mensink RP, Tan NS, Kersten S. ANGPTL4 is produced by entero-endocrine cells in the human intestinal tract. Histochem Cell Biol. 2014;141:383\u201391.","journal-title":"Histochem Cell Biol"},{"key":"8_CR51","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1128\/MCB.00858-12","volume":"33","author":"S Alex","year":"2013","unstructured":"Alex S, Lange K, Amolo T, Grinstead JS, Haakonsson AK, Szalowska E, et al. Short-chain fatty acids stimulate angiopoietin-like 4 synthesis in human colon adenocarcinoma cells by activating peroxisome proliferator-activated receptor. gamma Mol Cell Biol. 2013;33:1303\u201316.","journal-title":"gamma Mol Cell Biol"},{"key":"8_CR52","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1126\/science.1223813","volume":"336","author":"JK Nicholson","year":"2012","unstructured":"Nicholson JK, Holmes E, Kinross J, Burcelin R, Gibson G, Jia W, et al. Host-gut microbiota metabolic interactions. Science. 2012;336:1262\u20137.","journal-title":"Science"},{"key":"8_CR53","first-page":"1399","volume":"22","author":"AL Buchman","year":"1995","unstructured":"Buchman AL, Dubin MD, Moukarzel AA, Jenden DJ, Roch M, Rice KM, et al. Choline deficiency: a cause of hepatic steatosis during parenteral nutrition that can be reversed with intravenous choline supplementation. Hepatology. 1995;22:1399\u2013403.","journal-title":"Hepatology"},{"key":"8_CR54","doi-asserted-by":"publisher","first-page":"12511","DOI":"10.1073\/pnas.0601056103","volume":"103","author":"ME Dumas","year":"2006","unstructured":"Dumas ME, Barton RH, Toye A, Cloarec O, Blancher C, Rothwell A, et al. Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice. Proc Natl Acad Sci U S A. 2006;103:12511\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"8_CR55","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3945\/an.114.007955","volume":"7","author":"JL Sherriff","year":"2016","unstructured":"Sherriff JL, O\u2019Sullivan TA, Properzi C, Oddo JL, Adams LA. Choline, its potential role in nonalcoholic fatty liver disease, and the case for human and bacterial genes. Adv Nutr. 2016;7:5\u201313.","journal-title":"Adv Nutr"},{"key":"8_CR56","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.cmet.2011.07.013","volume":"14","author":"N Krahmer","year":"2011","unstructured":"Krahmer N, Guo Y, Wilfling F, Hilger M, Lingrell S, Heger K, et al. Phosphatidylcholine synthesis for lipid droplet expansion is mediated by localized activation of CTP: phosphocholine cytidylyltransferase. Cell Metab. 2011;14:504\u201315.","journal-title":"Cell Metab"},{"key":"8_CR57","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.bbalip.2012.08.009","volume":"1831","author":"O Geiger","year":"2013","unstructured":"Geiger O, Lopez-Lara IM, Sohlenkamp C. Phosphatidylcholine biosynthesis and function in bacteria. Biochim Biophys Acta. 2013;1831:503\u201313.","journal-title":"Biochim Biophys Acta"},{"key":"8_CR58","doi-asserted-by":"publisher","first-page":"e02481","DOI":"10.1128\/mBio.02481-14","volume":"6","author":"KA Romano","year":"2015","unstructured":"Romano KA, Vivas EI, Amador-Noguez D, Rey FE. Intestinal microbiota composition modulates choline bioavailability from diet and accumulation of the proatherogenic metabolite trimethylamine-N-oxide. MBio. 2015;6:e02481.","journal-title":"MBio"},{"key":"8_CR59","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1053\/j.gastro.2010.11.049","volume":"140","author":"MD Spencer","year":"2011","unstructured":"Spencer MD, Hamp TJ, Reid RW, Fischer LM, Zeisel SH, Fodor AA. Association between composition of the human gastrointestinal microbiome and development of fatty liver with choline deficiency. Gastroenterology. 2011;140:976\u201386.","journal-title":"Gastroenterology"},{"key":"8_CR60","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.mib.2013.07.002","volume":"16","author":"WR Russell","year":"2013","unstructured":"Russell WR, Hoyles L, Flint HJ, Dumas ME. Colonic bacterial metabolites and human health. Curr Opin Microbiol. 2013;16:246\u201354.","journal-title":"Curr Opin Microbiol"},{"key":"8_CR61","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1097\/MPG.0b013e31821f9b85","volume":"52","author":"P Vajro","year":"2011","unstructured":"Vajro P, Mandato C, Licenziati MR, Franzese A, Vitale DF, Lenta S, et al. Effects of lactobacillus rhamnosus strain GG in pediatric obesity-related liver disease. J Pediatr Gastroenterol Nutr. 2011;52:740\u20133.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"8_CR62","first-page":"1090","volume":"15","author":"R Aller","year":"2011","unstructured":"Aller R, De Luis DA, Izaola O, Conde R, Gonzalez Sagrado M, Primo D, et al. Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients: a double blind randomized clinical trial. Eur Rev Med Pharmacol Sci. 2011;15:1090\u20135.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"8_CR63","doi-asserted-by":"publisher","first-page":"7386","DOI":"10.3168\/jds.2014-8500","volume":"97","author":"S Nabavi","year":"2014","unstructured":"Nabavi S, Rafraf M, Somi MH, Homayouni-Rad A, Asghari-Jafarabadi M. Effects of probiotic yogurt consumption on metabolic factors in individuals with nonalcoholic fatty liver disease. J Dairy Sci. 2014;97:7386\u201393.","journal-title":"J Dairy Sci"},{"key":"8_CR64","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1111\/apt.12758","volume":"39","author":"A Alisi","year":"2014","unstructured":"Alisi A, Bedogni G, Baviera G, Giorgio V, Porro E, Paris C, et al. Randomised clinical trial: the beneficial effects of VSL#3 in obese children with non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2014;39:1276\u201385.","journal-title":"Aliment Pharmacol Ther"},{"key":"8_CR65","doi-asserted-by":"publisher","first-page":"72","DOI":"10.3164\/jcbn.11-38","volume":"50","author":"RY Xu","year":"2012","unstructured":"Xu RY, Wan YP, Fang QY, Lu W, Cai W. Supplementation with probiotics modifies gut flora and attenuates liver fat accumulation in rat nonalcoholic fatty liver disease model. J Clin Biochem Nutr. 2012;50:72\u20137.","journal-title":"J Clin Biochem Nutr"},{"key":"8_CR66","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/ismej.2014.99","volume":"9","author":"J Wang","year":"2015","unstructured":"Wang J, Tang H, Zhang C, Zhao Y, Derrien M, Rocher E, et al. Modulation of gut microbiota during probiotic-mediated attenuation of metabolic syndrome in high fat diet-fed mice. ISME J. 2015;9:1\u201315.","journal-title":"ISME J"},{"key":"8_CR67","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1097\/01.mcg.0000165671.25272.0f","volume":"39","author":"C Loguercio","year":"2005","unstructured":"Loguercio C, Federico A, Tuccillo C, Terracciano F, D\u2019Auria MV, De Simone C, et al. Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases. J Clin Gastroenterol. 2005;39:540\u20133.","journal-title":"J Clin Gastroenterol"},{"key":"8_CR68","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/s10620-011-1887-4","volume":"57","author":"M Malaguarnera","year":"2012","unstructured":"Malaguarnera M, Vacante M, Antic T, Giordano M, Chisari G, Acquaviva R, et al. Bifidobacterium longum with fructo-oligosaccharides in patients with non alcoholic steatohepatitis. Dig Dis Sci. 2012;57:545\u201353.","journal-title":"Dig Dis Sci"},{"key":"8_CR69","doi-asserted-by":"publisher","first-page":"535","DOI":"10.3945\/ajcn.113.068890","volume":"99","author":"T Eslamparast","year":"2014","unstructured":"Eslamparast T, Poustchi H, Zamani F, Sharafkhah M, Malekzadeh R, Hekmatdoost A. Synbiotic supplementation in nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled pilot study. Am J Clin Nutr. 2014;99:535\u201342.","journal-title":"Am J Clin Nutr"},{"key":"8_CR70","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1017\/S0007114517000204","volume":"117","author":"F Mofidi","year":"2017","unstructured":"Mofidi F, Poustchi H, Yari Z, Nourinayyer B, Merat S, Sharafkhah M, et al. Synbiotic supplementation in lean patients with non-alcoholic fatty liver disease: a pilot, randomised, double-blind, placebo-controlled, clinical trial. Br J Nutr. 2017;117:662\u20138.","journal-title":"Br J Nutr"}],"container-title":["Advances in Experimental Medicine and Biology","Obesity, Fatty Liver and Liver Cancer"],"original-title":[],"link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-981-10-8684-7_8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,6,28]],"date-time":"2018-06-28T07:30:01Z","timestamp":1530171001000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-981-10-8684-7_8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"ISBN":["9789811086830","9789811086847"],"references-count":70,"URL":"https:\/\/doi.org\/10.1007\/978-981-10-8684-7_8","relation":{},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"value":"0065-2598","type":"print"},{"value":"2214-8019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018]]}}}